Serotype Distribution in Hospitalized Adult With Pneumococcal Community Acquired Pneumonia in France

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1017 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-09

Study Completion Date

2025-02-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CAP'Hospi is an observational, multicentric study in France which primary objective is to describe the proportion of Community Acquired Pneumonia due to serotypes included in PCV20 among adults hospitalized for CAP

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Description of Pneumococcal Pneumonia

NCT03322670

Community-acquired Pneumonia

COMPLETED

Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia

NCT05903352

Community-Acquired Pneumonia

RECRUITING PHASE3

Costs, Health Status and Outcomes of CAP (Community-Acquired Pneumonia)

NCT00812084

Pneumonia

COMPLETED

A Global Active Surveillance for Community Acquired Pneumonia

NCT00929721

Community Acquired Pneumonia

COMPLETED NA

Measure of Vaccine Effectiveness to Prevent Hospitalizations for Viral Respiratory Infections in Adults

NCT05582239

Severe Acute Respiratory Infection (SARI) Influenza COVID-19

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia Pneumococcal Infections Community-acquired Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults 18 years of age or older
2. Admission to hospital for at least 24 hours
3. Suspicion of community-acquired pneumonia at admission defined as the association of: Radiologic findings consistent with pneumonia (eg, pleural effusion, increased pulmonary density due to infection and/or alveolar infiltrates \[multilobar, lobar, or segmental\] containing air bronchograms), AND The presence of ≥2 of the following signs or symptoms: Fever (oral temperature \>38°C or tympanic temperature \>38.5°C) in the 24 hours preceding admission; Hypothermia (\<35.5°C measured by a healthcare provider) in the 24 hours preceding admission ; Chills or rigors ; Pleuritic chest pain ; New or worsening cough ; Sputum production ; Dyspnea (shortness of breath); Tachypnea (respiratory rate \>20/min) ; Malaise ; Abnormal auscultatory findings suggestive of pneumonia (rales or evidence of pulmonary consolidation)
4. Written informed consent from the patient

Exclusion Criteria

1. Suspicion of tuberculosis
2. Individuals placed under judicial protection
3. Individuals who refuse the transfer of biological samples to the USA
4. Patient developing signs and symptoms of pneumonia after having been hospitalized for 48 hours or more
5. Pregnancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No